FAAH Inhibitor Compounds for Solubility and Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent fatty acid amide hydrolase (FAAH) inhibitors or modulators with improved properties to treat conditions mediated by FAAH activity, such as pain, inflammation, anxiety, and other disorders involving the endocannabinoid system.
Innovation Solution
Development of novel compounds of Formula (I-IV) and their prodrugs, pharmaceutically acceptable salts, and active metabolites, which act as FAAH modulators or inhibitors, slowing the degradation of endogenous endocannabinoid ligands like anandamide, thereby increasing cannabinoid receptor stimulation and providing therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing FAAH inhibitors are developed, then therapeutic effects are achieved, but solubility and bioavailability are insufficient
Solution Approach 1:
The patent modifies the chemical structure of FAAH inhibitors by changing parameters such as substituting different heteroaryl groups (pyridyl, pyrimidinyl, triazinyl), altering alkyl chain lengths, and introducing various functional groups (halogens, hydroxyl, methoxy). These parameter changes in the molecular structure improve solubility and oral bioavailability while maintaining therapeutic efficacy.
Solution Approach 2:
The patent creates composite molecular structures combining heteroaryl rings with specific substituents and linkers to form new FAAH inhibitor compounds. These composite structures integrate multiple functional elements that collectively improve both therapeutic effect and pharmacokinetic properties including solubility and bioavailability.
2Reliability
If FAAH inhibition is increased, then endocannabinoid levels increase, but cross-reactivity to other enzymes increases
Solution Approach 1:
The patent designs inhibitors with specific local structural features that target FAAH's unique active site characteristics. By incorporating heteroaryl groups with specific substitution patterns and spatial arrangements, the compounds achieve selective binding to FAAH while minimizing interaction with other enzymes, thus reducing cross-reactivity.
Solution Approach 2:
The heteroaryl-substituted urea and carbamate structures act as intermediaries that specifically mediate the interaction between the inhibitor and FAAH. These structural intermediaries are designed to fit the FAAH active site geometry and chemistry, providing selective inhibition without triggering off-target effects on other enzymes.
3Duration of action of stationary object
If plasma stability is improved, then drug half-life increases, but metabolic degradation may increase
Solution Approach 1:
The patent employs bioisosteric replacements and metabolic stabilization strategies where specific heteroaryl groups and substituents protect against metabolic degradation. These structural modifications create compounds that resist enzymatic breakdown in plasma, effectively extending half-life without requiring high doses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds exhibit improved solubility, plasma stability, and oral bioavailability, with reduced cross-reactivity to other enzymes, enhancing their efficacy in treating conditions like pain, inflammation, and anxiety.
Implementation Method 1
Fatty acid amide hydrolase (FAAH) is a member of the serine hydrolase family of enzymes capable of modulating the endocannabinoid system (eCB). It is primarily responsible for catalyzing the inactivation of endocannabinoid anandamide (AEA) via hydrolysis to arachidonic acid and ethanolamine.
Data Source
AI summary
The present disclosure relates to fatty acid amide hydrolase (FAAH) modulators, inhibitors, or FAAH modulators and inhibitors and methods and uses thereof. The FAAH modulators, inhibitors, or FAAH modulators and inhibitors may be compounds having Formula I, II, III or IV. Pharmaceutical compositions comprising the FAAH modulators, inhibitors, or FAAH modulators and inhibitors are also provided.